PPH vs PJP: Which Pharma ETF Should You Buy Now?
Two major pharmaceutical ETFs go head-to-head. Here's how to pick the right one for your portfolio.
Pharmaceutical ETFs give you broad exposure to one of the most defensive sectors in the market — and right now, two names dominate the conversation: VanEck's PPH and Invesco's PJP. Both funds target drug makers, but they're built differently, and that difference matters more than most retail traders realize.
PPH tracks a market-cap-weighted index of the largest global pharmaceutical companies, meaning your money is heavily concentrated in the biggest players — think mega-cap names with steady dividends and deep pipelines. If you want a blue-chip pharma bet with less volatility, that structure works in your favor. The global tilt also gives you exposure beyond U.S. borders, which can be a hedge or a headache depending on dollar strength.
Read more SpaceX Insider Share Unlock Timeline: What Retail Traders Need to Know →
PJP takes a different approach. Invesco's fund uses an equal-weighted methodology across U.S.-listed pharma stocks, which flattens the influence of any single giant and gives mid-cap names more room to move your returns. Equal-weighting tends to outperform in bull runs for the sector but can drag harder when sentiment turns. It's a higher-conviction, higher-volatility play compared to PPH.
The tradeable angle here is straightforward: if you're playing defense — rotating out of growth into safety — PPH gives you the smoother ride. If you think a specific catalyst like drug approvals or pricing reform is going to lift the whole sector, PJP's equal-weight structure lets smaller names amplify your gains. Neither fund is objectively better; they're tools for different market environments and risk tolerances.
Before you pull the trigger on either, check current expense ratios, holdings overlap, and liquidity. Small differences in cost and volume add up fast when you're trading actively. Continue reading at Yahoo Finance.
